Pfizer management commentary cites non-COVID product growth as driver of Q3 2026 performance

• Pfizer management commentary raised full-year 2026 revenue guidance to $62 billion-$64 billion, citing non-COVID product growth and disciplined execution.
• Adjusted diluted EPS guidance rose to $2.95-$3.05, absorbing a $0.10-per-share charge related to the Innovent transaction.
• Third-quarter revenue reached $16.6 billion, exceeding management expectations as non-COVID products grew 7% operationally, offset by lower COVID-19 product revenue.
• Adjusted diluted EPS reached $0.87, including the $0.10 Innovent charge, with cost discipline and improved productivity supporting earnings.
• Launched and acquired products generated $3.8 billion in revenue, up 32% operationally, primarily driven by Padcev, Nurtec and Lorbrena.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.